MDM2: A Therapeutic Target?
Chapter 2Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society (LLS), discusses the potential of targeting MDM2 for hematologic cancers.
The Future Focus of LLS Research
Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society (LLS), discusses how she is directing the LLS’s research focus.
p53 Dysregulation: Causes and Effects
Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society (LLS), discusses the role of p53 in oncogenesis and the proliferation of various cancers.
Combination Therapies for Multiple Myeloma
Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society (LLS), discusses the complexity and potential of the many possible treatment combinations now available for patients with multiple myeloma.
The Future of Treating Hematologic Cancers
Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society (LLS), discusses how the treatment of hematologic cancers is likely to change, including the roles biomarkers and epigenetics are likely to play in personalized care.
